Clinical Trials in Springfield Illinois

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1

Plasma-based Colorectal Cancer Screening Research & Development
NCT04027790
Condition: Colo-rectal Cancer
Intervention: Diagnostic Test: Epi proColon
Sponsor: Epigenomics, Inc
Recruiting
Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass
NCT02109367
Condition: Ovarian Cancer
Intervention:
Sponsors: Southern Illinois University; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting
MK-3475/BCG in High Risk Superficial Bladder Cancer
NCT02324582
Condition: Bladder Cancer
Intervention: Drug: Intravenous MK-3475/ Intravesical BCG
Sponsors: Southern Illinois University; Merck Sharp & Dohme Corp.
Recruiting
N-Force Screws Augmented With N-Force Blue in Hip Fractures
NCT03807349
Conditions: Intracapsular Proximal Femur Fracture; Garden Grade I Subcapital Fracture of Femoral Neck; Garden Grade II Subcapital Fracture of Femoral Neck
Intervention: Device: N-Force Screws Augmented with N-Force Blue
Sponsor: Zimmer Biomet
Recruiting
Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation
NCT03729830
Condition: Paroxysmal Atrial Fibrillation
Intervention: Device: Boston Scientific Open Irrigated Ablation Catheters
Sponsor: Boston Scientific Corporation
Recruiting
Work Ability in Young Adult Cancer Survivors
NCT03148080
Condition: Cancer Survivor
Interventions: Procedure: Cognitive Assessment; Other: Questionnaire Administration
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
NCT02921256
Conditions: Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7
Interventions: Drug: Capecitabine; Drug: Fluorouracil; Radiation: Intensity-Modulated Radiation Therapy; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Biological: Pembrolizumab; Drug: Veliparib
Sponsor: National Cancer Institute (NCI)
Recruiting
Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
NCT02761057
Conditions: Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Drug: Crizotinib; Drug: Savolitinib; Drug: Sunitinib; Drug: Sunitinib Malate
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826
Condition: Breast Carcinoma
Interventions: Other: Health Education Program; Other: Weight Loss Intervention
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group
Recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944
Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Intervention: Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02562716
Conditions: Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma
Interventions: Drug: Fluorouracil; Drug: Gemcitabine Hydrochloride; Drug: Irinotecan Hydrochloride; Drug: Oxaliplatin; Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure: Pancreatectomy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Conditions: Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
Conditions: Lymphoma; Malignant Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Plasma Cell Leukemia; Plasma Cell Myeloma; Progressive Disease; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Plasma Cell Myeloma; Spread of Lymphoma
Intervention: Other: Cytology Specimen Collection Procedure
Sponsor: National Cancer Institute (NCI)
Recruiting
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
NCT02466971
Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Stage IB2 Cervical Cancer AJCC v6 and v7; Stage II Cervical Cancer AJCC v7; Stage II Vaginal Cancer AJCC v6 and v7; Stage IIA Cervical Cancer AJCC v7; Stage IIB Cervical Cancer AJCC v6 and v7; Stage III Vaginal Cancer AJCC v6 and v7; Stage IIIB Cervical Cancer AJCC v6 and v7; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVA Vaginal Cancer AJCC v6 and v7; Vaginal Adenocarcinoma; Vaginal Adenosquamous Carcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions: Drug: Cisplatin; Radiation: External Beam Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Radiation: Internal Radiation Therapy; Other: Laboratory Biomarker Analysis; Radiation: Radiation Therapy; Drug: Triapine
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060
Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Afatinib Dimaleate; Drug: Binimetinib; Drug: Capivasertib; Drug: Copanlisib; Drug: Copanlisib Hydrochloride; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Dasatinib; Drug: Defactinib; Drug: Defactinib Hydrochloride; Drug: Erdafitinib; Drug: FGFR Inhibitor AZD4547; Drug: Ipatasertib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Drug: Larotrectinib Sulfate; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Ulixertinib; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Conditions: ALK Gene Rearrangement; ALK Gene Translocation; ALK Positive; Stage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Laboratory Biomarker Analysis
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Conditions: Lung Adenocarcinoma; Lung Large Cell Carcinoma; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IB Lung Squamous Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage II Lung Squamous Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Squamous Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Squamous Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Erlotinib Hydrochloride; Biological: Nivolumab; Other: Placebo
Sponsor: National Cancer Institute (NCI)
Recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282
Conditions: ALK Gene Rearrangement; EGFR Exon 19 Deletion Mutation; EGFR NP_005219.2:p.L858R; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Erlotinib Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Placebo
Sponsor: National Cancer Institute (NCI)
Recruiting
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
NCT02177695
Condition: Bladder Cancer
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Methotrexate; Drug: Vinblastine; Drug: Doxorubicin; Drug: Filgrastim
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
NCT02004275
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide; Drug: ixazomib; Drug: dexamethasone
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Celgene Corporation; Millennium Pharmaceuticals, Inc.
Recruiting
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT02003222
Conditions: Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; BCR/ABL1 Fusion Protein Negative; Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Biological: Blinatumomab; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Daunorubicin Hydrochloride; Drug: Dexamethasone; Drug: Etoposide; Other: Laboratory Biomarker Analysis; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Pegaspargase; Drug: Prednisone; Biological: Rituximab; Drug: Vincristine Sulfate
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
NCT01901094
Conditions: Stage II Breast Cancer; Stage IIIA Breast Cancer
Interventions: Procedure: Axillary Lymph Node Dissection (ALND); Radiation: Nodal Radiation Therapy; Radiation: Axillary Radiation Therapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181
Conditions: Adult Germ Cell Tumor; Childhood Extracranial Germ Cell Tumor; Childhood Germ Cell Tumor; Extragonadal Embryonal Carcinoma; Grade 2 Ovarian Teratoma; Malignant Germ Cell Tumor; Malignant Ovarian Teratoma; Stage I Ovarian Choriocarcinoma; Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage I Ovarian Teratoma AJCC v6 and v7; Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7; Stage I Testicular Choriocarcinoma AJCC v6 and v7; Stage I Testicular Embryonal Carcinoma AJCC v6 and v7; Stage I Testicular Yolk Sac Tumor AJCC v6 and v7; Stage II Ovarian Choriocarcinoma; Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7; Stage II Testicular Choriocarcinoma AJCC v6 and v7; Stage II Testicular Embryonal Carcinoma AJCC v6 and v7; Stage II Testicular Yolk Sac Tumor AJCC v6 and v7; Stage III Ovarian Choriocarcinoma; Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7; Stage III Testicular Choriocarcinoma AJCC v6 and v7; Stage III Testicular Embryonal Carcinoma AJCC v6 and v7; Stage III Testicular Yolk Sac Tumor AJCC v6 and v7; Stage IV Ovarian Choriocarcinoma; Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7; Testicular Mixed Choriocarcinoma and Embryonal Carcinoma; Testicular Mixed Choriocarcinoma and Teratoma; Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Interventions: Other: Best Practice; Drug: Bleomycin; Biological: Bleomycin Sulfate; Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Drug: Etoposide Phosphate; Other: Laboratory Biomarker Analysis; Other: Pharmacogenomic Study; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva
NCT01595061
Conditions: Stage IIIA Vulvar Cancer AJCC v7; Stage IIIB Vulvar Cancer AJCC v7; Stage IIIC Vulvar Cancer AJCC v7; Stage IVA Vulvar Cancer AJCC v7; Vulvar Squamous Cell Carcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Radiation: Intensity-Modulated Radiation Therapy; Procedure: Therapeutic Conventional Surgery
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting
S0820, Adenoma and Second Primary Prevention Trial
NCT01349881
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
NCT01101451
Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Stage I Cervical Cancer AJCC v6 and v7; Stage IA Cervical Cancer AJCC v6 and v7; Stage IB Cervical Cancer AJCC v6 and v7; Stage IIA Cervical Cancer AJCC v7
Interventions: Drug: Cisplatin; Radiation: External Beam Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
NCT01042522
Conditions: Ovarian Granulosa Cell Tumor; Ovarian Gynandroblastoma; Ovarian Sertoli-Leydig Cell Tumor; Ovarian Sex Cord Tumor With Annular Tubules; Ovarian Sex Cord-Stromal Tumor; Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types; Ovarian Steroid Cell Tumor
Interventions: Biological: Bleomycin Sulfate; Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide Phosphate; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NCT00632853
Condition: Lung Cancer
Interventions: Radiation: Standard Radiation Dose Therapy; Drug: cisplatin; Drug: etoposide; Radiation: High Radiation Dose Therapy; Drug: carboplatin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
NCT03952585
Conditions: Basaloid Squamous Cell Carcinoma; CDKN2A-p16 Positive; Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal Squamous Cell Carcinoma; Papillary Squamous Cell Carcinoma; Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Drug: Cisplatin; Radiation: Image Guided Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Biological: Nivolumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
NCT04001829
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Drug: Docetaxel; Drug: Paclitaxel; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Recruiting
Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors
NCT03996265
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Cancer Fatigue; Cancer Survivor; Complete Remission; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Drug: Bupropion Hydrochloride Controlled-release; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Gary Morrow; National Cancer Institute (NCI)
Recruiting
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
NCT03971474
Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Docetaxel; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Biological: Pembrolizumab; Drug: Pemetrexed; Drug: Pemetrexed Disodium; Biological: Ramucirumab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382
Conditions: Bladder Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Small Cell Carcinoma; Bladder Squamous Cell Carcinoma; Bone Lesion; Chromophobe Renal Cell Carcinoma; Infiltrating Bladder Lymphoepithelioma-Like Carcinoma; Infiltrating Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelial Carcinoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Small Cell Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Bladder Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Testicular Leydig Cell Tumor; Testicular Sertoli Cell Tumor
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Condition: Previously Treated Non-Small Cell Lung Cancer
Intervention: Drug: Screening Platform
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
NCT03839940
Condition: Malignant Neoplasm
Interventions: Drug: Dexamethasone; Other: Placebo; Other: Questionnaire; Other: Quality-of-Life Assessment; Drug: Everolimus
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Nivolumab Versus Observation in Treating Patients With Locally Advanced, Intermediate Risk HPV-Positive Oropharyngeal Cancer
NCT03811015
Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Human Papillomavirus-16 Positive; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Smoker
Interventions: Drug: Cisplatin; Radiation: Intensity-Modulated Radiation Therapy; Biological: Nivolumab; Other: Patient Observation
Sponsor: National Cancer Institute (NCI)
Recruiting
Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
NCT03793179
Conditions: Lung Non-Squamous Non-Small Cell Carcinoma; PD-L1 Positive; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8
Interventions: Drug: Carboplatin; Biological: Pembrolizumab; Drug: Pemetrexed
Sponsor: National Cancer Institute (NCI)
Recruiting
Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer
NCT03793166
Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Malignant Neoplasm in the Viscera; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
Interventions: Drug: Cabozantinib; Biological: Ipilimumab; Biological: Nivolumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
NCT03768414
Conditions: Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)
NCT03737994
Conditions: ALK Gene Rearrangement; ALK Positive; Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Alectinib; Drug: Brigatinib; Drug: Carboplatin; Drug: Ceritinib; Drug: Cisplatin; Drug: Crizotinib; Drug: Ensartinib; Drug: Lorlatinib; Drug: Pemetrexed
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29
Interventions: Other: Usual care disease monitoring; Other: Serum Tumor Marker directed disease monitoring; Other: Quality-of-Life Assessment; Other: Anxiety Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
NCT03712605
Conditions: Pathologic Stage I Merkel Cell Carcinoma AJCC v8; Pathologic Stage II Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8; Pathologic Stage III Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8; Resected Mass
Interventions: Other: Best Practice; Biological: Pembrolizumab; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Genetic Analysis of Blood and Tissue Samples From Participants With Advanced Cancer
NCT03707574
Conditions: Advanced Melanoma; Advanced Renal Cell Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
Intervention: Procedure: Biospecimen Collection
Sponsor: National Cancer Institute (NCI)
Recruiting
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
NCT03701308
Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin; Drug: Uproleselan
Sponsor: National Cancer Institute (NCI)
Recruiting
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
NCT03701282
Conditions: CCND1/IGHG1 Fusion Negative; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; t(11;14) Negative
Interventions: Drug: Ibrutinib; Biological: Obinutuzumab; Other: Quality-of-Life Assessment; Drug: Venetoclax
Sponsor: National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
NCT03698019
Conditions: Acral Lentiginous Melanoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Mucosal Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Biological: Pembrolizumab; Procedure: Therapeutic Conventional Surgery
Sponsor: National Cancer Institute (NCI)
Recruiting
Gemcitabine Hydrochloride and Cisplatin in Treating Participants With Invasive Bladder Urothelial Cancer
NCT03609216
Conditions: Infiltrating Bladder Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma; Stage III Bladder Urothelial Carcinoma
Interventions: Drug: Gemcitabine Hydrochloride; Drug: Cisplatin; Biological: Pegfilgrastim; Procedure: Conventional Surgery; Procedure: Radical Cystectomy; Other: Chemoradiotherapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
NCT03578081
Condition: Malignant Neoplasm
Interventions: Drug: Palonosetron Hydrochloride; Drug: Ondansetron Hydrochloride; Drug: Dexamethasone; Drug: Fosaprepitant Dimeglumine; Drug: Olanzapine; Other: Placebo
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
NCT03499808
Conditions: Amorphous, Eosinophilic, and Acellular Deposit; Constipation; Diarrhea; Early Satiety; Gastrointestinal Hemorrhage; Hepatomegaly; Lymphadenopathy; Macroglossia; Nausea; Primary Systemic Amyloidosis; Purpura; Recurrent Primary Amyloidosis; Refractory Primary Amyloidosis
Interventions: Biological: Isatuximab; Other: Laboratory Biomarker Analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Conditions: Cardiotoxicity; HER2/Neu Positive; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Carvedilol; Other: Laboratory Biomarker Analysis; Other: Patient Observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT03414970
Conditions: Ductal Breast Carcinoma; Invasive Breast Carcinoma; Lobular Breast Carcinoma; Medullary Breast Carcinoma; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Tubular Breast Carcinoma
Interventions: Radiation: Radiation Therapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment; Other: Laboratory Biomarker Analysis; Radiation: Hypofractionated Radiation Therapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
NCT03371719
Conditions: PSA Progression; Stage III Prostate Adenocarcinoma; Stage IV Prostate Adenocarcinoma
Interventions: Drug: Apalutamide; Radiation: External Beam Radiation Therapy; Other: Placebo
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669
Conditions: Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma
Interventions: Drug: Bendamustine; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Lenalidomide; Biological: Obinutuzumab; Drug: Prednisone; Drug: Umbralisib; Drug: Vincristine; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
NCT03244384
Conditions: Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions: Other: Clinical Observation; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab; Other: Pharmacological Study; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711
Conditions: Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage IIB Anal Cancer AJCC v8; Stage IIIA Anal Cancer AJCC v8; Stage IIIB Anal Cancer AJCC v8; Stage IIIC Anal Cancer AJCC v8
Interventions: Biological: Nivolumab; Other: Patient Observation
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
NCT03228537
Conditions: Biphasic Mesothelioma; Epithelioid Mesothelioma; Stage I Pleural Malignant Mesothelioma AJCC v7; Stage IA Pleural Malignant Mesothelioma AJCC v7; Stage IB Pleural Malignant Mesothelioma AJCC v7; Stage II Pleural Malignant Mesothelioma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7
Interventions: Drug: Atezolizumab; Drug: Cisplatin; Procedure: Extrapleural Pneumonectomy; Drug: Pemetrexed Disodium; Procedure: Pleurectomy; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Non-metastatic Colorectal Cancer Receiving Chemotherapy
NCT03186638
Conditions: Caregiver; Cognitive Impairment; Stage 0 Colorectal Cancer AJCC v6 and v7; Stage I Colorectal Cancer AJCC v6 and v7; Stage II Colorectal Cancer AJCC v7; Stage IIA Colorectal Cancer AJCC v7; Stage IIB Colorectal Cancer AJCC v7; Stage IIC Colorectal Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7
Interventions: Drug: Ibuprofen; Other: Placebo; Other: Questionnaire Administration
Sponsors: Gary Morrow; National Cancer Institute (NCI)
Recruiting
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT03087708
Conditions: Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: Naloxegol; Other: Placebo; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Stepped-Care Telehealth for Distress in Rural Cancer Survivors
NCT03060096
Conditions: Anxiety; Depressive Symptoms; Sleep Disturbance; Recurrent Disease; Fatigue; Quality of Life; Cancer
Interventions: Other: Severe Anxiety/depression: High Intensity Stepped Care; Other: Moderate Anxiety/depression: Low Intensity Stepped care; Other: Enhanced Usual Care Control
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
NCT02954874
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
NCT02927249
Condition: Node Positive HER2 Negative Breast Cancer
Interventions: Other: Placebo; Drug: Aspirin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group
Recruiting
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559
Conditions: Colon Adenocarcinoma; DNA Repair Disorder; Lynch Syndrome; Stage III Colon Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7
Interventions: Drug: Atezolizumab; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
NCT02856581
Condition: Lung Carcinoma
Interventions: Drug: Varenicline; Drug: Placebo; Other: Tobacco Cessation Counseling
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Pfizer
Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02224781
Conditions: BRAF NP_004324.2:p.V600X; Metastatic Melanoma; Progressive Disease; Recurrent Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma
Interventions: Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Biological: Ipilimumab; Biological: Nivolumab; Other: Quality-of-Life Assessment; Drug: Trametinib; Drug: Trametinib Dimethyl Sulfoxide
Sponsor: National Cancer Institute (NCI)
Recruiting
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01896999
Conditions: Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
NCT03204916
Condition: Acute Lymphoblastic Leukemia
Interventions: Other: Medical Chart Review; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435
Conditions: Alveolar Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Rhabdomyosarcoma; Sclerosing Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma; Untreated Childhood Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Drug: Irinotecan Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration; Radiation: Radiation Therapy; Drug: Temsirolimus; Drug: Vincristine Sulfate; Drug: Vinorelbine
Sponsor: National Cancer Institute (NCI)
Recruiting
Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
NCT03654768
Condition: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Drug: Dasatinib; Other: Laboratory Biomarker Analysis; Drug: Nilotinib; Drug: Ruxolitinib Phosphate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
NCT03375320
Conditions: Atypical Carcinoid Tumor; Carcinoid Tumor; Digestive System Neuroendocrine Neoplasm; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Atypical Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Neuroendocrine Neoplasm; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Serotonin-Producing Pancreatic Neuroendocrine Tumor; Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7; Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7; Stage IV Digestive System Neuroendocrine Tumor AJCC v7
Interventions: Drug: Cabozantinib S-malate; Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting
DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
NCT03321513
Condition: Diabetic Macular Edema
Interventions: Drug: intravitreous aflibercept; Drug: Bevacizumab + Deferred Aflibercept Group
Sponsor: Jaeb Center for Health Research
Recruiting
Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer
NCT03199885
Conditions: Breast Adenocarcinoma; HER2/Neu Positive; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Atezolizumab; Drug: Paclitaxel; Biological: Pertuzumab; Other: Placebo; Other: Quality-of-Life Assessment; Biological: Trastuzumab
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
NCT02997228
Conditions: Colorectal Adenocarcinoma; Mismatch Repair Deficiency; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
Interventions: Drug: Atezolizumab; Biological: Bevacizumab; Drug: Fluorouracil; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02502266
Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib; Drug: Cediranib Maleate; Other: Laboratory Biomarker Analysis; Drug: Olaparib; Drug: Paclitaxel; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Other: Questionnaire Administration; Drug: Topotecan; Drug: Topotecan Hydrochloride
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Precision Event Monitoring for Patients With Heart Failure Using HeartLogic™
NCT03579641
Conditions: Heart Failure; Defibrillators, Implantable; Monitoring, Physiologic; Cardiac Resynchronization Therapy; Cardiovascular Disease; Heart Disease
Intervention: Device: HeartLogic™ Sensors
Sponsor: Boston Scientific Corporation
Recruiting
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT03845296
Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Loss of Heterozygosity; Lung Non-Small Cell Squamous Carcinoma; Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Intervention: Drug: Rucaparib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
NCT03091660
Conditions: Stage 0 Bladder Urothelial Carcinoma; Stage 0is Bladder Urothelial Carcinoma; Stage I Bladder Urothelial Carcinoma
Interventions: Biological: BCG Solution; Biological: BCG Tokyo-172 Strain Solution; Biological: BCG Tokyo-172 Strain Vaccine; Other: Laboratory Biomarker Analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
NCT03809663
Condition: Atopic Dermatitis
Interventions: Drug: Tezepelumab; Other: Placebo
Sponsors: Amgen; AstraZeneca
Recruiting
EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation
NCT03200340
Condition: Stomatitis
Interventions: Drug: EC-18; Drug: Placebo
Sponsor: Enzychem Lifesciences Corporation
Recruiting
Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)
NCT02922036
Condition: Heart Failure
Intervention: Device: WiSE System
Sponsor: EBR Systems, Inc.
Recruiting
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
NCT03882970
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Tirzepatide; Drug: Insulin Degludec
Sponsor: Eli Lilly and Company
Recruiting
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03834753
Conditions: Age-related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration
Interventions: Biological: bevacizumab; Biological: ranibizumab
Sponsor: Outlook Therapeutics, Inc.
Recruiting
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
NCT03830281
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: LY900014; Drug: Insulin Lispro
Sponsor: Eli Lilly and Company
Recruiting
A Study of RO7105705 in Patients With Moderate Alzheimer's Disease
NCT03828747
Condition: Alzheimer's Disease
Interventions: Drug: RO7105705; Drug: Placebo; Drug: [18F]GTP1
Sponsor: Genentech, Inc.
Recruiting
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
NCT03823300
Condition: Wet Macular Degeneration
Interventions: Drug: Faricimab; Drug: Aflibercept; Drug: Sham Procedure
Sponsor: Hoffmann-La Roche
Recruiting
Sleep for Stroke Management and Recovery Trial
NCT03812653
Conditions: Ischemic Stroke; Sleep Apnea; Sleep Apnea, Obstructive; TIA; Stroke; CPAP; Telemedicine; Home Sleep Apnea Test; Randomized Clinical Trial; Multicenter Trial
Intervention: Device: CPAP
Sponsors: University of Michigan; National Institute of Neurological Disorders and Stroke (NINDS); FusionHealth LLC; Medical University of South Carolina; University of Cincinnati
Recruiting
Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
NCT03811002
Conditions: Limited Stage Lung Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Atezolizumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Radiation: Intensity-Modulated Radiation Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Diabetic Gastroparesis Study 05
NCT03786380
Condition: Gastroparesis
Intervention: Drug: Relamorelin 10 μg
Sponsor: Allergan
Recruiting
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265
Conditions: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Bladder Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8; Stage III Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8
Interventions: Drug: Atezolizumab; Drug: Cisplatin; Drug: Fluorouracil; Drug: Gemcitabine; Drug: Mitomycin; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Other: Survey Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
NCT03720470
Conditions: Dermatitis; Dermatitis, Atopic; Eczema; Skin Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases, Eczematous; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases
Interventions: Drug: PF-04965842 100 mg; Drug: PF-04965842 200 mg; Drug: Dupilumab; Drug: Oral Placebo; Drug: Injectable Placebo
Sponsor: Pfizer
Recruiting
Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
NCT03692403
Condition: Endometriosis-related Pain
Interventions: Drug: Quinagolide 360 µg; Drug: Quinagolide 720 µg; Drug: Quinagolide 1080 µg; Drug: Placebo
Sponsor: Ferring Pharmaceuticals
Recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308
Condition: Psoriatic Arthritis
Interventions: Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor: AbbVie
Recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
NCT03671148
Condition: Psoriatic Arthritis
Interventions: Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor: AbbVie
Recruiting
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT03669588
Condition: Generalized Myasthenia Gravis
Interventions: Biological: ARGX-113; Biological: Placebo
Sponsor: argenx BVBA
Recruiting
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
NCT03662204
Conditions: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Bladder Cancer; Uterine Cancer; Kidney Cancer; Renal Pelvis Cancer; Pancreatic Cancer; Liver Cancer; Stomach Cancer; Ovarian Cancer; Esophageal Cancer
Intervention: Other: Blood Sample Collection
Sponsor: Exact Sciences Corporation
Recruiting
Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
NCT03624881
Condition: Paroxysmal Atrial Fibrillation
Intervention: Device: Catheter ablation with EPU
Sponsor: Biosense Webster, Inc.
Recruiting
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
NCT03622593
Condition: Diabetic Macular Edema
Interventions: Drug: Aflibercept; Drug: Faricimab; Drug: Sham Procedure
Sponsor: Hoffmann-La Roche
Recruiting
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
NCT03614260
Conditions: Hypertension; Vascular Diseases; Cardiovascular Diseases
Interventions: Device: Paradise Renal Denervation System; Procedure: Renal Angiogram
Sponsor: ReCor Medical, Inc.
Recruiting
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03611751
Condition: Psoriasis
Interventions: Drug: BMS-986165; Other: Placebo; Drug: Apremilast
Sponsor: Bristol-Myers Squibb
Recruiting
Study of BHV-4157 in Alzheimer's Disease
NCT03605667
Condition: Alzheimer Disease
Interventions: Drug: troriluzole; Drug: Placebo oral capsule
Sponsors: Biohaven Pharmaceuticals, Inc.; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
NCT03595566
Condition: Clostridium Difficile Infection
Interventions: Drug: ridinilazole; Drug: vancomycin
Sponsor: Summit Therapeutics
Recruiting
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
NCT03595553
Condition: Clostridium Difficile Infection
Interventions: Drug: ridinilazole; Drug: vancomycin
Sponsor: Summit Therapeutics
Recruiting
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
NCT03574597
Conditions: Overweight; Obesity
Interventions: Drug: Semaglutide; Drug: Placebo (semaglutide)
Sponsor: Novo Nordisk A/S
Recruiting
Dysport in Hallux Abducto Valgus (HAV) Phase IIa
NCT03569098
Condition: Hallux Abductovalgus
Interventions: Biological: Botulinum toxin type A; Drug: Placebo
Sponsor: Ipsen
Recruiting
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
NCT03541174
Condition: Resistant Hypertension
Interventions: Drug: Aprocitentan 12.5 mg; Drug: Aprocitentan 25 mg; Drug: Placebo
Sponsors: Idorsia Pharmaceuticals Ltd.; Janssen Biotech, Inc.
Recruiting
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246
Conditions: Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Newly Diagnosed; FIGO Stage III-IV; Partial Response; Complete Response
Interventions: Drug: Rucaparib; Drug: Nivolumab; Drug: Placebo Oral Tablet; Drug: Placebo IV Infusion
Sponsors: Clovis Oncology, Inc.; Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological Oncological Trial Groups (ENGOT); Foundation Medicine
Recruiting
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
NCT03475186
Conditions: Glioblastoma; Radiotherapy; Complications; Cognitive Decline; Chemoradiation
Intervention: Drug: Ramipril
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
NCT03444870
Condition: Alzheimer Disease
Interventions: Drug: Gantenerumab; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting
Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02
NCT03426345
Conditions: Gastroparesis; Diabetes Mellitus
Interventions: Drug: Relamorelin; Drug: Placebo
Sponsor: Allergan
Recruiting
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
NCT03383146
Conditions: Gastroparesis; Diabetes Mellitus
Interventions: Drug: Relamorelin; Drug: Placebo
Sponsor: Allergan
Recruiting
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
NCT03350815
Condition: Ankylosing Spondylitis
Interventions: Drug: 150 mg open-label secukinumab; Drug: 150 mg double-blinded secukinumab; Drug: 300 mg double-blinded secukinumab
Sponsor: Novartis Pharmaceuticals
Recruiting
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
NCT03315143
Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Diseases
Interventions: Drug: Sotagliflozin (SAR439954); Drug: Placebo
Sponsor: Sanofi
Recruiting
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
NCT03258554
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Squamous Cell Carcinoma of Unknown Primary; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biological: Cetuximab; Biological: Durvalumab; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group; NRG Oncology
Recruiting
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
NCT03241459
Conditions: Peripheral Arterial Disease; Peripheral Vascular Disease; Artery Disease, Peripheral; Femoropopliteal Artery Occlusion
Interventions: Device: Surmodics SurVeil DCB; Device: Medtronic IN.PACT Admiral DCB
Sponsor: SurModics, Inc.
Recruiting
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
NCT03192215
Condition: Stroke
Interventions: Drug: Apixaban; Drug: Aspirin
Sponsors: Columbia University; National Institute of Neurological Disorders and Stroke (NINDS); University of Cincinnati; Medical University of South Carolina; Bristol-Myers Squibb; Pfizer; Roche Pharma AG; Weill Medical College of Cornell University; University of Washington
Recruiting
ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
NCT03183128
Condition: Clostridium Difficile Infection
Interventions: Drug: SER-109; Drug: Placebo
Sponsor: Seres Therapeutics, Inc.
Recruiting
CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
NCT03179800
Conditions: Hypertension; Resistant Hypertension
Interventions: Device: MobiusHD; Other: Sham Implantation
Sponsor: Vascular Dynamics, Inc.
Recruiting
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771
Conditions: Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT); Drug: Docetaxel; Drug: Gemcitabine; Radiation: Intensity-Modulated Radiation Therapy (IMRT); Drug: Pemetrexed Disodium; Radiation: Stereotactic Body Radiation Therapy (SBRT); Drug: Erlotinib Hydrochloride; Drug: Pembrolizumab
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
NCT03123588
Condition: MPN (Myeloproliferative Neoplasms)
Interventions: Drug: Ruxolitinib; Drug: Anagrelide; Drug: Placebo
Sponsor: Incyte Corporation
Recruiting
The DETOUR II Clinical Study
NCT03119233
Condition: Peripheral Arterial Disease
Intervention: Device: PQ Bypass System
Sponsor: PQ Bypass, Inc.
Recruiting
Strategic Management to Optimize Response To Cardiac Resynchronization Therapy
NCT03089281
Condition: Heart Failure
Intervention: Device: CRT-D
Sponsor: Boston Scientific Corporation
Recruiting
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013
Conditions: Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Adrenal Gland; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pancreas; Metastatic Malignant Neoplasm in the Skin; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Renal Cell Carcinoma; Oligometastasis; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma
Interventions: Procedure: Conventional Surgery; Biological: Nivolumab; Other: Patient Observation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
NCT02928497
Condition: Stroke
Interventions: Device: WATCHMAN LAAC Device Implant; Drug: Single Antiplatelet Therapy or No Therapy (Control)
Sponsor: Boston Scientific Corporation
Recruiting
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
NCT02924727
Condition: Acute Myocardial Infarction
Interventions: Drug: LCZ696 (sacubitril/valsartan); Drug: Ramipril; Drug: Placebo of LCZ696; Drug: Placebo of ramipril; Drug: Valsartan; Drug: Placebo of valsartan
Sponsor: Novartis Pharmaceuticals
Recruiting
Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
NCT02923193
Condition: Peripheral Arterial Disease
Interventions: Device: Shockwave Lithoplasty® Peripheral Lithoplasty System; Drug: Medtronic IN.PACT (DCB)
Sponsor: Shockwave Medical, Inc.
Recruiting
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
NCT02876835
Condition: Anaemia
Interventions: Drug: Daprodustat; Drug: Darbepoetin alfa; Drug: Placebo; Drug: Iron Therapy
Sponsor: GlaxoSmithKline
Recruiting
The PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis
NCT02675114
Condition: Aortic Stenosis
Interventions: Procedure: Surgical aortic valve replacement (SAVR); Device: Transcatheter Aortic Valve Replacement (TAVR)
Sponsor: Edwards Lifesciences
Recruiting
A Study of the ReCor Medical Paradise System in Clinical Hypertension
NCT02649426
Conditions: Hypertension; Vascular Diseases
Interventions: Device: The Paradise® Renal Denervation Ultrasound System; Device: Sham Procedure
Sponsor: ReCor Medical, Inc.
Recruiting
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
NCT02635009
Conditions: Extensive Stage Small Cell Lung Carcinoma; Limited Stage Small Cell Lung Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Other: Cognitive Assessment; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: NRG Oncology; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting
TandemHeart Experiences and MEthods (THEME Registry)
NCT02326402
Conditions: Heart Diseases; Lung Diseases
Intervention: Device: TandemHeart System
Sponsor: CardiacAssist, Inc.
Recruiting
Baroreflex Activation Therapy for Heart Failure
NCT02627196
Condition: Heart Failure
Interventions: Device: BAROSTIM NEO® System; Drug: Medical Management
Sponsor: CVRx, Inc.
Recruiting
Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms
NCT02489539
Condition: Aortic Aneurysm, Abdominal
Intervention: Device: GORE® EXCLUDER® Conformable AAA Endoprosthesis
Sponsor: W.L.Gore & Associates
Recruiting
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
NCT02364557
Conditions: Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer
Interventions: Radiation: Stereotactic Radiosurgery; Procedure: Therapeutic Conventional Surgery; Other: Laboratory Biomarker Analysis
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
NCT02314169
Conditions: Anal Canal Squamous Cell Carcinoma; Metastatic Anal Canal Carcinoma; Stage IV Anal Canal Cancer AJCC v6 and v7
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma
NCT03914625
Conditions: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Blasts More Than 25 Percent of Bone Marrow Nucleated Cells; Down Syndrome
Interventions: Drug: Asparaginase Erwinia chrysanthemi; Biological: Blinatumomab; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Leucovorin; Drug: Leucovorin Calcium; Drug: Mercaptopurine; Drug: Mercaptopurine Oral Suspension; Drug: Methotrexate; Drug: Prednisolone; Drug: Prednisone; Drug: Thioguanine; Drug: Vincristine; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179086
Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: photon beam radiation therapy; Radiation: proton beam radiation therapy; Drug: temozolomide; Other: laboratory biomarker analysis
Sponsors: NRG Oncology; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NCT02135042
Conditions: Epstein-Barr Virus Infection; Stage II Nasopharyngeal Carcinoma; Stage III Nasopharyngeal Carcinoma; Stage IVA Nasopharyngeal Carcinoma; Stage IVB Nasopharyngeal Carcinoma
Interventions: Drug: Cisplatin; Other: Clinical Observation; Drug: Fluorouracil; Drug: Gemcitabine Hydrochloride; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Quality-of-Life Assessment
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
NCT02089217
Condition: Carotid Stenosis
Interventions: Procedure: Carotid endarterectomy (CEA); Device: Carotid Stenting (CAS); Other: Intensive Medical Management - no CEA; Other: Intensive Medical Management - no CAS
Sponsors: Thomas G. Brott, M.D.; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting
Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia
NCT02060630
Condition: Critical Limb Ischemia
Interventions: Procedure: Open surgical revascularization; Device: Endovascular revascularization
Sponsors: New England Research Institutes; Brigham and Women's Hospital; Massachusetts General Hospital; Boston Medical Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
NCT01954992
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Glufosfamide; Drug: Fluorouracil
Sponsor: Eleison Pharmaceuticals LLC.
Recruiting
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
NCT01805076
Conditions: Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Triple-negative Breast Cancer
Interventions: Procedure: Breast surgery; Procedure: Magnetic resonance imaging; Procedure: Mammography
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); American College of Radiology Imaging Network
Recruiting
Connect® MDS/AML Disease Registry
NCT01688011
Conditions: Myelodysplastic Syndromes; Acute Myeloid Leukemia
Intervention:
Sponsor: Celgene
Recruiting
ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)
NCT01534819
Condition: Aortic Aneurysm
Interventions: Device: EndoAnchor™; Procedure: endovascular treament
Sponsor: Medtronic Endovascular
Recruiting
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
NCT02724579
Conditions: CTNNB1 Gene Mutation; Medulloblastoma; Wnt Positive
Interventions: Drug: Cisplatin; Drug: Cyclophosphamide; Other: Laboratory Biomarker Analysis; Drug: Lomustine; Radiation: Radiation Therapy; Drug: Vincristine; Drug: Vincristine Sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
NCT02723994
Condition: Leukemia
Interventions: Drug: Ruxolitinib; Drug: Asparaginase Erwinia Chrysanthemi; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Doxorubicin; Drug: Leucovorin Calcium; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Pegaspargase; Drug: Prednisone; Drug: Thioguanine; Drug: Vincristine Sulfate
Sponsors: Incyte Corporation; Children's Oncology Group
Recruiting
Project: Every Child for Younger Patients With Cancer
NCT02402244
Conditions: Central Nervous System Neoplasm; Childhood Immature Teratoma; Childhood Langerhans Cell Histiocytosis; Childhood Malignant Neoplasm; Childhood Mature Teratoma; Congenital Mesoblastic Nephroma; Desmoid-Type Fibromatosis; Lymphoproliferative Disorder; Myeloproliferative Neoplasm; Stromal Neoplasm
Interventions: Other: Cytology Specimen Collection Procedure; Other: Medical Chart Review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853
Condition: B Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Drug: Asparaginase; Biological: Blinatumomab; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Etoposide; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Mitoxantrone Hydrochloride; Drug: Pegaspargase; Other: Pharmacological Study; Drug: Therapeutic Hydrocortisone; Drug: Thioguanine; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
Psoriasis Longitudinal Assessment and Registry (PSOLAR)
NCT00508547
Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: Ustekinumab; Biological: Biological therapies other than infliximab, ustekinumab and guselkumab; Drug: Conventional systemic agents; Biological: Infliximab; Biological: Guselkumab
Sponsor: Janssen Scientific Affairs, LLC
Recruiting
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
NCT01096368
Conditions: Cellular Ependymoma; Childhood Anaplastic Ependymoma; Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Clear Cell Ependymoma; Ependymoma; Newly Diagnosed Childhood Ependymoma; Papillary Ependymoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Carboplatin; Drug: Cisplatin; Other: Clinical Observation; Drug: Cyclophosphamide; Drug: Etoposide; Other: Laboratory Biomarker Analysis; Drug: Vincristine Sulfate Liposome
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241
Conditions: Ganglioneuroblastoma; Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Study of Kidney Tumors in Younger Patients
NCT00898365
Conditions: Clear Cell Sarcoma of the Kidney; Congenital Mesoblastic Nephroma; Diffuse Hyperplastic Perilobar Nephroblastomatosis; Rhabdoid Tumor of the Kidney; Stage I Kidney Wilms Tumor; Stage I Renal Cell Cancer AJCC v6 and v7; Stage II Kidney Wilms Tumor; Stage II Renal Cell Cancer AJCC v7; Stage III Kidney Wilms Tumor; Stage III Renal Cell Cancer AJCC v7; Stage IV Kidney Wilms Tumor; Stage IV Renal Cell Cancer AJCC v7; Stage V Kidney Wilms Tumor
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Lung Cancer Screening Protocol
NCT03958253
Condition: Lung Cancer Screening
Intervention: Other: Toolbox for Lung Cancer Screening
Sponsors: Washington University School of Medicine; BJC HealthCare, Barnes-Jewish St. Peters Hospital; Decatur Memorial Hospital; Memorial Health System; Sarah Bush Lincoln Health System; Southern Illinois Healthcare; Cox Health Systems
Recruiting
ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement
NCT03735667
Condition: Aortic Stenosis
Interventions: Device: ACURATE neo2™ Transfemoral TAVR System; Device: Medtronic CoreValve TAVR System; Device: Edwards SAPIEN 3 TAVR System
Sponsor: Boston Scientific Corporation
Recruiting
A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418
Condition: Cancer
Intervention: Drug: Atezolizumab
Sponsor: Hoffmann-La Roche
Recruiting
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
NCT02663908
Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Leuprolide
Sponsors: Ferring Pharmaceuticals; Memorial Sloan Kettering Cancer Center; Duke Clinical Research Institute
Recruiting
The Coflex®COMMUNITY Study: An Observational Study of Coflex® Interlaminar Technology
NCT02457468
Condition: Spinal Stenosis
Intervention: Device: coflex
Sponsors: Predicted, Reported and Observed Outcomes Foundation; SPIRITT Research
Recruiting
Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
NCT02202434
Condition: Aortic Stenosis
Interventions: Device: Lotus Valve System; Device: CoreValve/Evolut R Transcatheter Aortic Valve Replacement System; Device: LOTUS Edge Valve System
Sponsor: Boston Scientific Corporation
Recruiting
International Guillain-Barré Syndrome Outcome Study
NCT01582763
Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsor: Erasmus Medical Center
Recruiting
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Conditions: Acute Lymphoblastic Leukemia; Brain Neoplasm; Hematopoietic Cell Transplantation Recipient; Hodgkin Lymphoma; Osteosarcoma; Rhabdomyosarcoma
Interventions: Procedure: Assessment of Therapy Complications; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting

Menu

Categories

Recent Listings

Post your clinical trial on JoinClinicalTrials.com

JoinClinicalTrials.com

Results

Post your clinical trial on JoinClinicalTrials.com

Popular Now